Auxilium's (AUXL) Testosterone Gel Growth Encouraging, Say Analysts

Article Related Press Releases (1) Related Articles (1) Stock Quotes (1) Comments (0)

Jefferies maintained a Buy on Auxilium Pharmaceuticals (NASDAQ: AUXL) and cuts its price target to $29.00 (from $32.00).

"AUXL reported lower-than-expected Testim revenue and announced the Xiaflex EU collaboration with Pfizer (NYSe: PFE) is ending, both contributing to lower revenue guidance," noted analyst Thomas Wei.

"However, we previously assumed a modest valuation contribution from Xiaflex EU royalties and are encouraged Testim guidance itself reflects expectations for near-term growth in 4Q12," added Wei.

For an analyst ratings summary and ratings history on Auxilium Pharmaceuticals click here. For more ratings news on Auxilium Pharmaceuticals click here.

Shares of Auxilium Pharmaceuticals closed at $18.60 yesterday, with a 52 week range of $14.28-$29.37.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: BofA/Merrill Lynch Downgrades Cliffs Natural Resources (CLF) to Underperform
• Lazard Raises PT on Chicago Bridge & Iron (CBI) to $75
• Brean Capital Downgrades Tetra Tech (TTEK) to Hold

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?